logo
Exclusive: Pinaults' Artemis says not facing financial strain despite Kering's woes

Exclusive: Pinaults' Artemis says not facing financial strain despite Kering's woes

Reuters2 days ago
PARIS, July 29 (Reuters) - A jump in standalone debt at Artemis, the Pinault family company that controls Gucci-owner Kering, is a "temporary spike", and the company is not facing any liquidity problems due to a drop in dividends from Kering and other assets, it told Reuters.
The investment vehicle also said that none of its debt was tied to Kering's (PRTP.PA), opens new tab share price performance in the terms - or covenants - agreed with lenders, as some investors have speculated.
Privately-owned Artemis, chaired by outgoing Kering boss Francois-Henri Pinault, is the top investor in the French fashion and leather goods heavyweight, with a 43% stake, and controls it through a majority of voting rights.
It has become the subject of increased scrutiny from investors after Reuters reported it had accumulated high debt across its portfolio as it sought to diversify investments.
Some analysts are concerned the high debt level could limit Kering's ability to deliver a turnaround at struggling flagship label Gucci, at a time when major rivals such as Louis Vuitton owner LVMH (LVMH.PA), opens new tab are investing heavily in their brands.
"We have no liquidity problems," Artemis said in a statement, responding to Reuters questions about its finances.
It added that the holding company had less than 500 million euros ($577 million) of debt maturing over the next two years, and more than one billion euros of available cash.
Artemis, which also owns 54% of Hollywood talent agency CAA and a 29% stake in sportswear maker Puma, has historically kept a low media and investor profile.
But annual accounts published alongside a recent bond issue give some insight into its finances.
Artemis' consolidated group debt stood at 26.7 billion euros at the end of 2024, almost double the amount of two years earlier. Kering, the largest asset consolidated in the accounts, held around 14 billion euros of total debt at the end of 2024, built up in large part to finance an acquisition strategy spearheaded by Pinault to counter a slowdown at Gucci.
On a standalone basis, which excludes operating businesses such as Kering, Artemis' debt was 7.1 billion euros as of May 31, the company said when announcing the bond issue last month.
Last year, Artemis paid 227 million euros in net interest charges to service its growing debt pile, Artemis' 2024 accounts show, up from just 60 million euros the year before.
In its statement, Artemis said the 7.1 billion euros of debt was a "temporary spike, only linked to the acquisition of CAA in 2023", which it said was driven by a desire to diversify beyond Europe and the luxury industry.
The value of the majority stake in the Hollywood talent agency, which represents A-listers like the Obamas and Scarlett Johansson, was $3.7 billion in Artemis' 2023 accounts. The whole agency has been valued at $7 billion.
Just as Artemis is spending more to service its debt, dividend payments from Kering, which accounted for more than 80% of its financial income in the last two years, are falling.
Kering slashed total dividends paid on its 2024 earnings, to 739 million euros from 1.7 billion euros a year earlier, after a string of profit warnings.
Barclays analysts estimate the payout may drop to 364 million euros in 2026 due to Kering's poor performance this year. Artemis is entitled to roughly 43% of Kering's payout.
Kering declined to comment.
Puma, which in the last two years contributed 35 million euros to Artemis' annual dividend income according to Artemis' accounts, also cut dividends paid out this year by roughly a third and warned it would be loss-making in 2025.
"It is incorrect to assume that we are dependent on Kering's dividend flows to finance the company. In fact, other companies in the Group pay regular and significant dividends which cover most of our debt servicing needs," Artemis said, without elaborating.
Besides its stakes in Kering, Puma and CAA, Artemis owns historic auction house Christie's, some exclusive wineries and a company offering polar cruises, all of which are unlisted.
Without Kering, Artemis' businesses generated a recurring operating profit of 48.9 million euros in 2024, up from a 115-million-euro loss the year before, its 2024 accounts show.
Kering shares have lost close to 60% of their value over the last 24 months, while Puma shares are down 66% in the same time.
In a recent note focusing on Artemis's finances, BofA analysts said trading activity and feedback they had received suggested some investors were worried that Artemis' loans might have covenants tying them to Kering's stock performance.
Artemis said such speculation was misplaced. "The Group has no financial covenants linked to Kering's share price", it said.
June's bond issue tied to Kering's share performance - worth 400 million euros and used to refinance an old bond linked to Puma's stock - was oversubscribed, Artemis said.
($1 = 0.8674 euros)
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Argentina oil and gas exports rise 36% in first half of year, business group says
Argentina oil and gas exports rise 36% in first half of year, business group says

Reuters

time15 minutes ago

  • Reuters

Argentina oil and gas exports rise 36% in first half of year, business group says

BUENOS AIRES, July 31 (Reuters) - Argentina's oil and gas exports rose 36% to $3.7 billion in the first half of the year, compared to the same period last year, Argentina's Chamber of Hydrocarbons Exploration and Production said in a statement on Thursday. The group added it expected exports to bring in more than $6 billion this year, and surpass a goal of $25 billion by the end of the decade.

Daimler Truck slashes key profit forecast on North America weakness
Daimler Truck slashes key profit forecast on North America weakness

Reuters

time15 minutes ago

  • Reuters

Daimler Truck slashes key profit forecast on North America weakness

FRANKFURT, July 31 (Reuters) - Daimler Truck ( opens new tab on Thursday slashed a key profit forecast for 2025 due to "continuous market weakness in North America". The German company now expects adjusted earnings before interest and taxes (EBIT) in a range of 3.6 billion euros to 4.1 billion euros ($4.1 billion to $4.7 billion), compared with 4.7 billion euros reported for 2024. That would mark a drop of as much as 23%. The company previously forecast that adjusted EBIT for 2025 would be just 5% lower, and could even rise 5%. ($1 = 0.8755 euros)

Bristol Myers tops revenue expectations on strength of older drugs, shares fall
Bristol Myers tops revenue expectations on strength of older drugs, shares fall

Reuters

time17 minutes ago

  • Reuters

Bristol Myers tops revenue expectations on strength of older drugs, shares fall

July 31 (Reuters) - Bristol Myers Squibb (BMY.N), opens new tab posted much better-than-expected second-quarter results on Thursday on strong sales of its best-selling brands, but failed to convince investors that newer products could drive future growth and shares fell nearly 5%. Revenue in the quarter, which analysts had expected to fall due to the loss of patent protection on some of its products, including blood cancer therapy Revlimid, rose 1% to $12.3 billion. Analysts, on average, were looking for revenue of $11.4 billion, according to LSEG data. The quarterly sales beat was driven by legacy products such as the blood thinner Eliquis, which is expected to face competition from cheaper generics next year, and demand for Revlimid, which has held up better than expected, said Raymond James analyst Sean McCutcheon. However, "investors don't see the beat as an indicator of future growth prospects," McCutcheon said. Sales of Eliquis, which Bristol Myers shares with Pfizer (PFE.N), opens new tab, rose 8% to $3.7 billion in the quarter, while cancer immunotherapy Opdivo brought in $2.6 billion, up 7% from a year ago. Analysts, on average, had forecast sales of $3.3 billion and $2.3 billion, respectively. Revlimid sales fell 38% to $838 million, but still topped analyst estimates by about $300 million. The U.S. drugmaker said it earned $2.9 billion, or $1.46 per share, down from $4.2 billion, or $2.07, a year earlier. Analysts had expected earnings of $1.07 a share. Bristol has been contending with a steep revenue decline from Revlimid, which raked in nearly $13 billion in 2021 but $5.8 billion last year due to generic competition. Some of its other cancer drugs such as Pomalyst, Sprycel and Abraxane are contending with the same issue. Still, Revlimid has performed better than initially feared, and the company now expects 2025 sales of around $3 billion, Chief Commercialization Officer Adam Lenkowsky said. The company had previously said it expected 2025 Revlimid sales to be closer to $2.5 billion. Investors are closely watching Bristol's newer products, including cell therapy Breyanzi and schizophrenia treatment Cobenfy, to gauge whether they can drive the next phase of growth as sales of older blockbuster treatments decline. McCutcheon said company comments suggest data from a trial testing Cobenfy for Alzheimer's disease may come a bit later than previously anticipated - by the end of this year rather than early fourth quarter. The company said it was conducting reviews of trial sites, which could delay reporting of results, but Bristol is still targeting by the end of this year. Bristol Myers raised its full-year revenue forecast to $46.5 billion to $47.5 billion from its prior view of $45.8 billion to $46.8 billion. Last month, Bristol agreed to pay up to $11.1 billion in a partnership deal with Germany's BioNTech ( opens new tab to develop next-generation cancer treatments that could take on rival Merck's (MRK.N), opens new tab best-selling immunotherapy Keytruda. Bristol recorded a charge of 57 cents per share in the second quarter related to the deal. Including the charge, it now expects full-year earnings to be $6.35 to $6.65 a share. Analysts are estimating 2025 earnings of around $6.24. Bristol's 2025 operating expenses forecast of $16.5 billion, up from its previous view of $16.2 billion, could be contributing to the share price decline, Piper Sandler analysts said.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store